Therefore, based on the findings from the present study and the accumulating body of clinical evidence with exenatide, therapy with GLP-1 receptor agonists may represent a promising approach for the treatment of patients with CHF or cardiovascular disease associated with type 2 diabetes, supporting the need for further research in this field. Here, GLP1R is linked to type 2 diabetes mellitus.